Partnerships news - the latest biotech news from Labiotech.eu

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Jim Cornall — Tue, 25 Jul 2023 09:00:00 +0000

Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […]

The post Roche and Alnylam to work on RNAi therapeutic to treat hypertension appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

Jim Cornall — Thu, 20 Jul 2023 15:00:00 +0000

TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […]

The post Mage Biologics created to develop oral antibody therapy for ulcerative colitis appeared first on Labiotech.eu.

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

Jim Cornall — Tue, 18 Jul 2023 09:00:00 +0000

DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […]

The post Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma appeared first on Labiotech.eu.

FDA approves Beyfortus ahead of 2023-24 RSV season

Jim Cornall — Tue, 18 Jul 2023 08:28:06 +0000

The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]

The post FDA approves Beyfortus ahead of 2023-24 RSV season appeared first on Labiotech.eu.

Lilly boosts obesity portfolio with Versanis Bio acquisition

Jim Cornall — Mon, 17 Jul 2023 15:25:13 +0000

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]

The post Lilly boosts obesity portfolio with Versanis Bio acquisition appeared first on Labiotech.eu.

Partnership to progress neurodegenerative disorder treatments

Jim Cornall — Thu, 13 Jul 2023 09:00:00 +0000

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

The post Partnership to progress neurodegenerative disorder treatments appeared first on Labiotech.eu.

Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden

Roohi Mariam Peter — Wed, 12 Jul 2023 15:17:31 +0000

With a combined market value of over $7 billion, the life science sectors in Sweden and Denmark are thriving, with over a thousand healthcare companies being set up over the past few years. Much of this is owing to the cross-border cluster that spans regions of eastern Denmark and southern Sweden, the Medicon Valley. Racking […]

The post Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden appeared first on Labiotech.eu.

Pfizer kicks $25M into CellCentric

Jim Cornall — Wed, 12 Jul 2023 12:00:00 +0000

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […]

The post Pfizer kicks $25M into CellCentric appeared first on Labiotech.eu.

Unlocking the power of mRNA technology

External Contributor — Tue, 11 Jul 2023 07:57:29 +0000

By Yochi Slonim, CEO and co-founder of Anima Biotech mRNA technology has gained widespread recognition due to its role in the development of vaccines, such as those used against COVID-19; however, the scope of mRNA extends far beyond vaccines, offering a range of applications for addressing different conditions. Vaccines represent a notable application of mRNA […]

The post Unlocking the power of mRNA technology appeared first on Labiotech.eu.

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Jim Cornall — Tue, 04 Jul 2023 09:32:25 +0000

Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]

The post Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment appeared first on Labiotech.eu.

AI program finds multiple influenza drug targets

Jim Cornall — Thu, 29 Jun 2023 09:48:48 +0000

Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]

The post AI program finds multiple influenza drug targets appeared first on Labiotech.eu.

Centogene and Lifera to form Saudi Arabian Joint Venture

Jim Cornall — Thu, 29 Jun 2023 09:19:04 +0000

Centogene N.V. and Lifera have announced a strategic collaboration with the formation of a joint venture (JV) to increase local and regional access and rapid delivery of multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). Under the terms of the collaboration, Centogene will receive a $30 million mandatory […]

The post Centogene and Lifera to form Saudi Arabian Joint Venture appeared first on Labiotech.eu.

Four biotech events to attend in South East Asia this year

Roohi Mariam Peter — Wed, 28 Jun 2023 15:17:19 +0000

The South East Asian biotech industry is one to reckon with. The growing biotech industry in the region has seen countries like Singapore and Thailand become prominent players in the commercialization of drugs, thanks to a rising emphasis on research and development. As governments in the eleven countries introduce policies that encourage biopharmaceutical research, with […]

The post Four biotech events to attend in South East Asia this year appeared first on Labiotech.eu.

European Coalition for Access to Comprehensive Genomic Profiling launched

Jim Cornall — Fri, 23 Jun 2023 09:15:00 +0000

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, have launched the European Coalition for Access to Comprehensive Genomic Profiling (ECGP), to improve cancer care through increased routine clinical access and reimbursement of Comprehensive Genomic Profiling (CGP) in Europe. CGP is a method of testing tumors that […]

The post European Coalition for Access to Comprehensive Genomic Profiling launched appeared first on Labiotech.eu.

BIO International Convention 2023: The Highlights

Dylan Kissane — Tue, 20 Jun 2023 12:00:00 +0000

BIO International Convention, one of the largest networking events hosted for the biotech industry, has been influential in helping biopharmas discover new opportunities and building and strengthening partnerships within the biotech and pharma community. This year, the event took place from June 5 to 8, in the bustling biotech hotspot of Boston, Massachusetts, and saw […]

The post BIO International Convention 2023: The Highlights appeared first on Labiotech.eu.

Trial shows colorectal cancer drug efficacy

Jim Cornall — Mon, 19 Jun 2023 13:00:02 +0000

HUTCHMED (China) Limited and Takeda have announced results of their phase III FRESCO‑2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC), which were published in The Lancet. Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3. FRESCO-2 is a global phase […]

The post Trial shows colorectal cancer drug efficacy appeared first on Labiotech.eu.

Researchers say open-source collaboration is ‘fundamental’

Jim Cornall — Thu, 15 Jun 2023 10:57:44 +0000

New Seqera Labs data have revealed that 72% of research scientists believe open-source collaboration and workflow management is now “fundamental” to the work they do. The data published by Seqera Labs, a provider of secure data orchestration software, brings together the views of 500 researchers and scientists who use open-source scientific workflow platforms for their […]

The post Researchers say open-source collaboration is ‘fundamental’ appeared first on Labiotech.eu.

‘Clinical trial in a dish’ for Alzheimer’s disease

Jim Cornall — Tue, 13 Jun 2023 12:49:19 +0000

Axol Bioscience Ltd., a pluripotent stem cell technology provider for drug discovery, has signed an agreement with StrataStem to access and commercialize its collection of Alzheimer’s disease (AD) patient samples. Harnessing its stem cell knowledge, Axol will reprogram these patient samples into induced pluripotent stem cells (iPSCs) that can then be differentiated into a wide […]

The post ‘Clinical trial in a dish’ for Alzheimer’s disease appeared first on Labiotech.eu.

MOSAIC spatial atlas of cancer cells to be created

Jim Cornall — Fri, 09 Jun 2023 09:30:00 +0000

Owkin, NanoString Technologies and cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, and Charité – Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting. MOSAIC is a $50 million project to revolutionize cancer research through the use […]

The post MOSAIC spatial atlas of cancer cells to be created appeared first on Labiotech.eu.